11.06.26 -- New Podcast Episodes: AI And Digital Twins In Bioprocessing, Tomorrow's CNS Breakthroughs, Advancing CGT Delivery

Check out the latest episodes from Better Biopharma, Cell & Gene: The Podcast, and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

Host Tyler Menichiello is joined by Tonix Pharmaceuticals' chief technical officer, Siobhan Fogarty, to discuss the planning and construction of its manufacturing facility in Dartmouth, MA, which was purpose-built for the production of its horsepox-based live viral vaccine platform, TNX-801.

In this episode, host Tyler Menichiello is joined by Will Olughu, Ph.D., global CMC lead and senior principal scientist at Ipsen, to talk about process modeling and AI applications in biopharma manufacturing.

On this episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo.

Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets, and the good and bad signs that emerge during diligence.

Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and biotech investing.

On this episode, Keith Murphy, CEO at Viscient Biosciences, unpacks how 3D human tissue models and scaffold-free bioprinting can change the way developers predict drug safety and model disease.

Host Erin Harris talks to Jonathan Rigby, President and CEO of Sernova (and proposed CEO of BetaNova) and Will Rust, PhD, President and CEO of Seraxis (and proposed President and Chief Scientific Officer of BetaNova). Sernova and Seraxis are coming together to form BetaNova, combining Sernova’s implantable Cell Pouch with Seraxis’ stem cell-derived pancreatic islet cells in an effort to develop a functional cell therapy for people living with Type 1 diabetes (T1D).

On this episode, Erin Harris speaks with Dr. Remo Moomiaie-Qajar of Axiom Biosciences about the company’s delivery-focused approach to developing regenerative and genetic medicines.